The Social Security Act in section
1861(dd) and Federal regulations in 42 CFR §418.106 and §
418.202(f) require hospice programs to provide individuals under
hospice care with drugs and biologicals related to the palliation
and management of the terminal illness as defined in the hospice
plan of care. Medicare payment is made to the hospice for each day
an eligible beneficiary is under the hospice's care, regardless of
the amount of services provided on any given day. Because hospice
care is a Medicare Part A benefit, drugs provided by the hospice
and covered under the Medicare payment to the hospice program are
not covered under Part D. The industry in conjunction with the
National Council for Prescription Drug Programs, (NCPDP) developed
a draft Medicare Part D Hospice Form to collect information
necessary for the Part D sponsor to override a hospice prior
authorization reject for beneficiaries enrolled in hospice. CMS
made minor revisions to the NCPDP form to create this Standardized
Form entitled Hospice Information for Medicare Part D Plans. This
PRA submission is a request for approval of the standardized form
available for use by Part D sponsors.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.